News
9/12/2016

ZeClinics receives €1.87M funding from the Horizon2020 SME Instrument Phase 2

ZeClinics receives €1.87M funding from the Horizon2020 SME Instrument Phase 2


News from ZeClinics


ZeClinics has been granted with the SME Instrument Phase 2 within the European Union framework Horizon 2020, category "Supporting Innovative SMEs in the healthcare biotechnology sector". The company, mono-beneficiary, receives € 1.87 million, 100% of the proposed budget for the project "ZeCardio: High-throughput cardiotoxicity screening (HTS) with zebrafish embryo".  

The grant will allow ZeClinics to develop and accelerate the commercialization, of one of their flagship products: ZeCardio. A predictive system for cardiovascular impact analysis during the drug discovery phase, which they expect will become the most advanced solution in the market. ZeCardio will have a high level of robotization that will allow evaluating hundreds of drugs daily, allowing ZeClinics to assess, with high predictive confidence, their possible cardiotoxic impact in humans.

More information:
ZeClinics website and CEXS-UPF website